Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 308
Selected: 0
NCT IDTitle
NCT01671956Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
NCT05202145Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
NCT01399593Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
NCT02324049Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT00952484Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
NCT05288816A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
NCT06160414A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
NCT04304144A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
NCT01997229Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
NCT01454986Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
NCT01335165Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04504825A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
NCT00037622Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
NCT00744042Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
NCT03124368A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
NCT03418389Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
NCT04609670Study of Radiolabeled ALXN2050 in Healthy Adult Males
NCT05556096Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT06079281Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079372Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT00739505Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
NCT03406507A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
NCT01758432Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
NCT04709094A Drug Interaction Study of Danicopan
NCT01176266Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
NCT00350272Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
NCT00312039Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
NCT05047523Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT01303952Therapy of Chronic Cold Agglutinin Disease With Eculizumab
NCT02145182Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
NCT07081646A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT05746559ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
NCT01419028A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
NCT01095887Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
NCT04999020Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
NCT04757259Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
NCT02293382A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
NCT02301624Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
NCT00375609Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT00675844An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
NCT02946463ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04970004Study in Adult and Pediatric Patients With HSCT-TMA
NCT04982289Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
NCT06183931Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT02128269Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
NCT04631562Study of ALXN1820 in Healthy Adult Participants
NCT04609696Study of the Metabolism of Danicopan in Healthy Adults